Lonza Inc., Hyglos Reach on Global Settlement Agreement for Endotoxin Detection Patents

Basel-headquartered Lonza Walkersville, Inc. and Hyglos GmbH, an internationally active German biotech company, announced that they have reached a mutually beneficial global settlement which includes a licence agreement for Hyglos under certain Lonza patents in the area of endotoxin detection. Specifically, the agreement allows Hyglos to use recombinant factor C technology protected by Lonza’s patents to produce Hyglos’ own endotoxin products. The agreement also includes the dismissal of the law suit Lonza previously filed against Hyglos. The terms of the settlement are confidential.